| Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker, A Knezevic, ... Journal of Clinical Oncology 40 (21), 2333, 2022 | 100 | 2022 |
| Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial SA Funt, M Lattanzi, K Whiting, H Al-Ahmadie, C Quinlan, MY Teo, ... Journal of Clinical Oncology 40 (12), 1312, 2022 | 64 | 2022 |
| Androgen‐deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: how much smoke and how much fire? DJ McHugh, JC Root, CJ Nelson, MJ Morris Cancer 124 (7), 1326-1334, 2018 | 47 | 2018 |
| Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: results of a phase 2 trial. CH Lee, MH Voss, MI Carlo, YB Chen, E Reznik, A Knezevic, ... Journal of Clinical Oncology 39 (15_suppl), 4509-4509, 2021 | 36 | 2021 |
| Management of biochemically recurrent prostate cancer: ensuring the right treatment of the right patient at the right time DE Spratt, DJ McHugh, MJ Morris, AK Morgans American Society of Clinical Oncology Educational Book 38, 355-362, 2018 | 34 | 2018 |
| A phase I trial of IGF-1R inhibitor cixutumumab and mTOR inhibitor temsirolimus in metastatic castration-resistant prostate cancer DJ McHugh, J Chudow, M DeNunzio, SF Slovin, DC Danila, MJ Morris, ... Clinical genitourinary cancer 18 (3), 171-178. e2, 2020 | 27 | 2020 |
| Adjuvant chemotherapy with etoposide plus cisplatin for patients with pathologic stage II nonseminomatous germ cell tumors DJ McHugh, SA Funt, D Silber, A Knezevic, S Patil, D O’Donnell, S Tsai, ... Journal of Clinical Oncology 38 (12), 1332, 2020 | 18 | 2020 |
| Conventional‐dose versus high‐dose chemotherapy for relapsed germ cell tumors DJ McHugh, DR Feldman Advances in urology 2018 (1), 7272541, 2018 | 18 | 2018 |
| A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer D McHugh, M Eisenberger, EI Heath, J Bruce, DC Danila, DE Rathkopf, ... Investigational new drugs 37, 1052-1060, 2019 | 15 | 2019 |
| Outcomes after multidisciplinary management of primary mediastinal germ cell tumors R Caso, GD Jones, MS Bains, M Hsu, KS Tan, DR Feldman, SA Funt, ... Annals of surgery 274 (6), e1099-e1107, 2021 | 14 | 2021 |
| Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors SA Funt, DJ McHugh, S Tsai, A Knezevic, D O'Donnell, S Patil, D Silber, ... The Oncologist 26 (6), 483-491, 2021 | 10 | 2021 |
| Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive biomarkers of pathologic complete response (pCR) in neoadjuvant breast cancer: an … S Rafee, DJ McHugh, M Greally, O Ayodele, N Keegan, M Lim, A Hassan, ... Annals of Oncology 27, vi532, 2016 | 8 | 2016 |
| Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma. MY Teo, N Ratna, AM Regazzi, DE Zimmerman, DJ McHugh, AL Laccetti, ... Journal of Clinical Oncology 39 (6_suppl), 458-458, 2021 | 7 | 2021 |
| A phase II, nonrandomized open trial assessing pain efficacy with radium-223 in symptomatic metastatic castration-resistant prostate cancer D McHugh, S Tagawa, N Moryl, M Milowsky, G Heller, J Osborne, ... Clinical Genitourinary Cancer 19 (5), 447-456, 2021 | 5 | 2021 |
| Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. CH Lee, KN Fitzgerald, MH Voss, MI Carlo, A Knezevic, L Peralta, ... Journal of Clinical Oncology 41 (16_suppl), 4537-4537, 2023 | 4 | 2023 |
| Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC). M Sternschuss, N Toumbacaris, JP Das, T Powles, DF Bajorin, ... Journal of Clinical Oncology 42 (16_suppl), 4581-4581, 2024 | 3 | 2024 |
| Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management. H Truong, V Ravichandran, Y Kemel, A Knezevic, JP Gleeson, N Benfante, ... Journal of Clinical Oncology 40 (16_suppl), 5007-5007, 2022 | 2 | 2022 |
| A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma. R Kotecha, CH Lee, DJ McHugh, C Dadoun, A Knezevic, MI Carlo, E Feld, ... Journal of Clinical Oncology 40 (6_suppl), 347-347, 2022 | 2 | 2022 |
| Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): the Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts). S Funt, DJ McHugh, S Tsai, D O'Donnell, A Knezevic, S Patil, D Silber, ... Journal of Clinical Oncology 36 (15_suppl), 4550-4550, 2018 | 2 | 2018 |
| Prevalence, clinico-pathological features and outcomes of ‘double-hit’high-grade B-cell non-Hodgkins lymphoma (NHL): a single institution experience DJ McHugh, P Gou, J Quinn, P Thornton, B Bird, S Sukor, A Fortune, ... Annals of Oncology 27, vi315, 2016 | 2 | 2016 |
